SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
Nomination recognizes SEED’s pioneering work in molecular glue development in targeted protein degradation to address high unmet medical needs Follows recent FDA IND clearance…
